CervoMed (CRVO) has shared new data from the Phase 2b RewinD-LB trial demonstrating neflamapimod treatment led to a significant reduction in the ...
Phase 2b study of neflamapimod at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference Data demonstrates neflamapimod treatment led to significant reductions in plasma glial fibrillary ...
SPYM's 12-month return is +14.7%, but index gains are skewed by mega-cap stocks; half of S&P 500 constituents have negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback